A carregar...
Re-examining the Meis Trial for Evidence of False-Positive Results
U.S. Food and Drug Administration (FDA)–approved 17α-hydroxyprogesterone caproate therapy is currently available to reduce recurrent preterm birth in the United States. This commentary reviews the original landmark Meis trial (“Prevention of Recurrent Preterm Delivery by 17 Alpha-Hydroxyprogesterone...
Na minha lista:
| Publicado no: | Obstet Gynecol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Lippincott Williams & Wilkins
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7431135/ https://ncbi.nlm.nih.gov/pubmed/32769653 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/AOG.0000000000003991 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|